Skip to main content

Table 4 CK levels and clinical features of 14 patients with Guillain–Barré syndrome with elevated CK levels

From: Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels

Patient
No.
Age/sexCKCranial nerve
involvement
Limb weaknessCMAP
amplitude
(mV)
Right median
nerve
TreatmentDisability
Time until
first elevation (days)
Time
until peak (days)
Level
at peak (U/L)
Arm or leg
dominant
Proximal or distal dominantSymmetric or
asymmetric
Time
until nadir (days)
At
nadir (HG)
14 days
after onset (HG)
28 days
after onset (HG)
120–29/M441937NoneArm dominantDistal dominantSymmetric0.5IVIG4211
230–39/M991264NoneNo dominanceNo dominanceSymmetric6.2IVIG2321
330–39/M1111795NoneArm dominantDistal dominantSymmetric3.2IVIG11221
420–29/M1624591NoneNo dominanceNo dominanceSymmetric7.1IVIG15221
530–39/M1114550Ophthalmoplegia,
Facial weakness,
bulbar weakness
No dominanceDistal dominantSymmetric7IVIG +
steroid pulse
4422
640–49/M210515NoneArm dominantDistal dominantSymmetric2.5IVIG4222
730–39/M99433NoneArm dominantDistal dominantSymmetric5.2None6220
830–39/M2528429Bulbar weaknessLeg dominantNo dominanceSymmetric0.5IVIG +
plasma exchange
10555
950–59/M77402NoneArm dominantNo dominanceAsymmetric7.5IVIG12111
1050–59/M24396NoneNo dominanceDistal dominantAsymmetric7IVIG5411
1140–49/F610351NoneNo dominanceNo dominanceSymmetric7.8IVIG8211
1240–49/M35319NoneNo dominanceNo dominanceSymmetric8.8IVIG4221
1340–49/M1016300NoneNo dominanceNo dominanceSymmetric2.5IVIG4432
1460–69/F55288NoneNo dominanceDistal dominantSymmetric7.5IVIG4321
  1. To anonymize the identifying information, specific ages were grouped into age ranges
  2. Abbreviations: CK Creatine kinase, CMAP Compound action potential, HG Hugh grade, IVIG Intravenous immunoglobulin